SRSofia Romero-Santos

Sofia Romero-Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sofia Romero-Santos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical Characteristics of Ocular Mucous Membrane Pemphigoid: A Systematic Review and Meta-Analysis

    by Natalia Bocanegra-Oyola, Daniella Pardo-Pizza, Carlos Cifuentes-González, María Valentina Oliver-Hernández, María Juliana Romero-Osorio, Sofía Romero-Santos, Daniela Parra-Tanoux, Ana M. Barragán, Alejandra De-La-Torre

    Mucous membrane pemphigoid (MMP) is a systemic, immune-mediated, chronic disease characterized by the development of subepithelial blisters due to the presence of autoantibodies directed against st...


  • Systemic and Bilateral Severe Ocular Toxoplasmosis Resembling Autoimmune Phenomena: A Case Report

    by Sofia Romero-Santos, Daniela Parra-Tanoux, Carlos Cifuentes-González, Juliana Muñoz-Ortiz, Germán Mejía-Salgado, Alejandra De-La-Torre

    PurposeTo present an atypical case of severe bilateral ocular toxoplasmosis with systemic involvement that initially mimicked an autoimmune etiology, posing challenges to its diagnosis and treatment.Case ReportA 39-year-old immunocompetent male was admitted to the hospital due to a presumed pulmonary thromboembolism concomitant with an abrupt onset of vision loss. Initial differential diagnoses included antiphospholipid syndrome and systemic lupus erythematosus, prompting the administration of corticosteroid pulses and rituximab. Despite observing a partial systemic response, there was no improvement in visual acuity. Subsequent aqueous humor polymerase chain reaction confirmed Toxoplasma gondii infection, leading to the introduction of oral antibiotic therapy. The patient's condition showed a partially favorable response; however, the treatment could not reverse the permanent retinal damage.Conclusion and importanceThis case underscores the importance of ruling out an infectious etiology in all cases of uveitis. Additionally, it alerts clinicians to the possibility that elevated positive autoantibodies may result from a severe inflammatory reaction caused by pathogens rather than an autoimmune or autoinflammatory disease, particularly in instances of poor treatment response or atypical clinical presentation.


  • Ibrutinib-Related Uveitis in Non-Hodgkin Lymphoma Patients: A Case Report and Literature Review

    by Rafael Mendez, Juan Sebastián Pineda-Sierra, Sofia Romero-Santos, Carlos Cifuentes-González, Silvina Bonaccorso, Cristobal Couto, Ariel Schlaen, Germán Mejía-Salgado, Alejandra De-La-Torre

    PurposeTo report two cases of ibrutinib-related uveitis and review the literature to date.MethodsWe report two cases of ibrutinib-related uveitis using CARE guidelines and review the cases reported in the literature.ResultsCase 1) A 55-year-old female with recurrent primary central nervous system lymphoma presented with bilateral decreased visual acuity, photophobia, and floaters that started one month after initiating oral treatment with ibrutinib. Chronic non-granulomatous bilateral anterior-intermediate uveitis with macular edema was identified. Secondary causes were ruled out, and a presumptive diagnosis of ibrutinib-related uveitis was made. Case 2) A 57-year-old female with Waldenstrom macroglobulinemia who was treated with ibrutinib for two years presented with bilateral blurred vision, photophobia, red eyes, and floaters. A diagnosis of non-granulomatous, noninfectious panuveitis with bilateral cystoid macular edema was made. Secondary causes were ruled out, and ibrutinib toxicity was the most likely cause.ConclusionIbrutinib-related uveitis is a novel and under-diagnosed clinical entity. The most frequent clinical presentation in the literature is bilateral, non-granulomatous, anterior, and intermediate uveitis. Macular edema is a frequent complication. Uveitis usually requires topical treatment and the suspension of ibrutinib. Switching to second-generation Bruton tyrosine kinase inhibitors is proposed as a potential therapeutic alternative.